| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC8A1 |
| Uniprot No | P32418 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 396-627aa |
| 氨基酸序列 | VNTEVTENDPVSKIFFEQGTYQCLENCGTVALTIIRRGGDLTNTVFVDFRTEDGTANAGSDYEFTEGTVVFKPGDTQKEIRVGIIDDDIFEEDENFLVHLSNVKVSSEASEDGILEANHVSTLACLGSPSTATVTIFDDDHAGIFTFEEPVTHVSESIGIMEVKVLRTSGARGNVIVPYKTIEGTARGGGEDFEDTCGELEFQNDEIVKTISVKVIDDEEYEKNKTFFLEIG |
| 预测分子量 | 27.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SLC8A1(NCX1)重组蛋白的3篇代表性文献及其简要摘要：
1. **文献名称**：*"Functional characterization of the cardiac Na⁺/Ca²⁺ exchanger NCX1.1 cloned from human heart"*
**作者**：Matsuoka S., et al.
**摘要**：该研究通过重组表达人源SLC8A1(NCX1)蛋白，分析了其在HEK293细胞中的离子转运活性，揭示了NCX1的钙依赖性调控机制及其在心肌细胞中的生理作用。
2. **文献名称**：*"Cryo-EM structure of the human sodium-calcium exchanger NCX1"*
**作者**：Liao J., et al.
**摘要**：利用冷冻电镜技术解析了重组NCX1蛋白的高分辨率三维结构，阐明了其钠/钙离子选择性结合的分子基础及转运循环的构象变化。
3. **文献名称**：*"A novel regulatory mechanism of the cardiac Na⁺/Ca²⁺ exchanger (NCX1) by phospholemman (PLM)"*
**作者**：Bossuyt J., et al.
**摘要**：通过重组NCX1与磷酸化调节蛋白PLM的共表达实验，揭示了PLM对NCX1转运活性的抑制作用及其在心力衰竭中的潜在病理意义。
4. **文献名称**：*"Expression and purification of the cardiac Na⁺/Ca²⁺ exchanger in Pichia pastoris for functional studies"*
**作者**：Hilge M., et al.
**摘要**：报道了在毕赤酵母系统中高效表达重组NCX1蛋白的方法，并通过体外重构验证了其离子转运功能，为大规模制备研究提供了技术参考。
这些文献涵盖了SLC8A1重组蛋白的结构、功能、调控及表达技术等方向，可作为相关研究的起点。
SLC8A1. also known as the sodium-calcium exchanger 1 (NCX1), is a membrane transport protein encoded by the SLC8A1 gene. It belongs to the solute carrier family 8 (SLC8), which mediates the bidirectional exchange of Na⁺ and Ca²⁺ across cellular membranes, utilizing the electrochemical gradient of sodium to regulate intracellular calcium levels. NCX1 plays a critical role in maintaining calcium homeostasis, particularly in excitable tissues such as cardiac muscle, where it facilitates the extrusion of Ca²⁺ during relaxation phases, thereby influencing contractility and electrical signaling. Dysregulation of NCX1 has been linked to cardiovascular diseases, including heart failure and arrhythmias.
Recombinant SLC8A1 protein is engineered for in vitro studies to dissect its structure-function relationships, transport mechanisms, and regulatory pathways. Produced using heterologous expression systems (e.g., mammalian, insect, or bacterial cells), the recombinant protein retains key functional domains, including nine transmembrane segments and a large intracellular loop critical for calcium sensing and allosteric modulation. Researchers employ it to investigate ion selectivity, pharmacological modulation (e.g., by KB-R7943 or SEA0400), and interactions with signaling molecules like phospholemman. Its applications extend to drug discovery, structural biology (cryo-EM studies), and disease modeling, offering insights into calcium dysregulation pathologies. The protein’s purification often involves affinity tags (e.g., His-tag) for isolation, followed by functional validation via liposome-based flux assays or electrophysiology. By enabling precise manipulation of NCX1 activity, recombinant SLC8A1 tools advance therapeutic strategies targeting calcium-related disorders.
×
